TY  - JOUR
AU  - Garcia-Marco, Jose A
AU  - Jimenez, Javier Lopez
AU  - Recasens, Valle
AU  - Fernandez-Zarzoso, Miguel 
AU  - Gonzalez-Barca, Eva
AU  - Somolinos-De-Marcos, Nieves 
AU  - Ramírez, M Jose
AU  - Peñalver-Parraga, Francisco Javier 
AU  - Yañez, Lucrecia
AU  - De-La-Serna-Torroba, Javier
AU  - Garcia-Malo, Maria Dolores 
AU  - Deben-Ariznavarreta, Guillermo 
AU  - Perez-Persona, Ernesto 
AU  - Ruiz-Guinaldo, M Angeles 
AU  - De-Paz-Arias, Raquel
AU  - Bañas-Llanos, Elena
AU  - Jarque, Isidro
AU  - Fernandez-Valle, M Del Carmen 
AU  - Carral-Tatay, Ana 
AU  - Perez-De-Oteyza, Jaime 
AU  - Donato-Martin, Eva Maria 
AU  - Perez-Fernandez, Inmaculada 
AU  - Martinez-Martinez, Rafael 
AU  - Andreu-Costa, M Angeles 
AU  - Champ, Diana
AU  - Garcia-Suarez, Julio 
AU  -  Gonzalez-Diaz, Marcos
AU  - Ferrer, Secundino
AU  - Carbonell, Felix
AU  - Garcia-Vela, Jose A
PY  - 2019
DO  - 10.3324/haematol.2018.204891
UR  - http://hdl.handle.net/10668/13733
T2  - Haematologica
AB  - It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this...
LA  - en
PB  - Fondazione Ferrata Storti
KW  - Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
KW  - Remission Induction
KW  - Rituximab
KW  - Treatment Outcome
KW  - Vidarabine
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cyclophosphamide
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Maintenance Chemotherapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm, Residual
KW  - Prognosis
TI  - High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
TY  - research article
VL  - 104
ER  -